Pasted image at 2017_11_08 09_29 PM.png
Screenshot 2017-11-13 09.40.34.png
John Santini #5 (May 2017).jpg
Pavone Headshot.jpg

Wade Beavers

Wade Beavers was a co-founder and CEO of DoApp Inc. and mRemedy where he lead the company to three successful product acquisitions. Beavers is currently President of Mobile for NEWSCYCLE Solutions, and also CEO of a new health start up uBody Inc. He has investments in technology solutions for wellness, agriculture, and commerce. Beavers and DoApp have been featured in Bloomberg, Vator News, MSNBC, ESPN Magazine, and in the New York Times best selling book, “The Entrepreneur Equation” by Carol Roth.


Julie Henry

Julie A. Henry is an Enterprise IP Contract Manager in Department of Business Development, Mayo Clinic Ventures at Mayo Clinic in Rochester, Minnesota.  Her responsibilities involve collaborating with internal and external customers as a resource to manage unique and complex intellectual property related contractual issues across the entire Mayo enterprise.  Additionally, she is involved in the evaluation, patent strategy and out-licensing of a portfolio of Mayo Clinic inventions.  Ms. Henry has been with Mayo Clinic for over twenty-five years.  She has had experience in all facets of the commercialization process including drafting, negotiating and management of agreements.  She has given presentations relating to licensing technologies as well as educating staff concerning intellectual property protection and commercialization. Before taking her position in Mayo Clinic Ventures, Ms. Henry was a Research Technician in the Peptide Synthesis Protein Sequencing Core Facility in Mayo Clinic’s Biochemistry and Molecular Biology Department. Ms. Henry received her B.A. from St. Cloud State University in St. Cloud, Minnesota and her Master of Business Administration from University of St. Thomas in Minneapolis, Minnesota. 


John T. Santini, Jr., PhD

Dr. Santini is a startup company executive, serial entrepreneur, inventor, and scientist that has spent his career focused on the creation and growth of businesses developing next-generation pharmaceuticals, drug delivery systems, biosensors, and mobile health products. Prior to his current roles as CEO of Vergent Bioscience and Board Member/co-founder of Univ. of Minnesota biotech spinout ApoGen Biotechnologies, he served as the CEO or CTO of four healthcare startups – MicroCHIPS, On Demand Therapeutics, RadioRx, and IRISense – developing products such as novel cancer therapeutics and imaging agents, laser-activated anti-VEGF implants for eye diseases, wireless implantable MEMS-based drug delivery and biosensor systems for osteoporosis and diabetes, and smartphone-based sensing systems for diabetes management. He has negotiated and executed collaborations with major pharmaceutical and medical device companies, and he has raised over $72M in venture capital and corporate funding for his companies. Dr. Santini has been honored as one of Popular Science Magazine’s “Brilliant Ten” and one of the Top 100 Young Innovators in the world by Technology Review Magazine. He has published in top scientific journals such as Nature, Nature Biotechnology, and Science Translational Medicine, has over 80 issued US and international patents, and his work resulted in a Technology Pioneer award from the World Economic Forum (Davos, Switzerland) and a Gold Medal from the Edison Awards in the Science and Medical, Game Changers category. Dr. Santini obtained his PhD in chemical engineering from MIT as a National Science Foundation Fellow and his BSE in chemical engineering from the University of Michigan.


Christine Beech

Christine Beech is the Executive Director of the Kabara Institute for Entrepreneurial Studies at Saint Mary’s University of Minnesota as well as an Assistant Professor of Business. Christine’s teaching, research and consulting experience are in the areas of strategic management, leadership development, contract management, succession planning, social entrepreneurship, and small business management. Prior to joining Saint Mary’s University, Christine worked in corporate entrepreneurship where she led the development of a multi-million dollar business line for a global consulting firm before launching her own consulting business in the Washington, D.C. area. Christine also served in the military, learning German and Russian and traveling the world as an intelligence officer. She holds a Master’s Degree in Management and is a Doctoral Candidate at UMUC writing her dissertation on Social Entrepreneurship in Faith-based Nonprofits. 


Perry Hackett

Perry Hackett is a co-founder of Recombinetics and serves as Chair of its Scientific Advisory Board. He is co-founder of gene therapy company, Discovery Genomics,  where he previously served as Chief Scientific Officer and Chairman. He is also a professor and research scientist in the University of Minnesota’s department of Genetics, Cell Biology and Development and co-founder of the Center for Genome Engineering.  Hackett has a degree in Physics from Stanford University, a PhD in Biophysics and Genetics from the University of Colorado, and did postdoctoral training at the Max Planck Institute for Cell Biology in Germany and at the University of California in San Francisco.


Carla Pavone

As Program Director of the Minnesota Innovation Corps (a site of the NSF-funded National I-Corps), Carla Pavone facilitates technology commercialization across the U of Minnesota by developing and coordinating educational and coaching programs for STEM students, post-docs, research staff and faculty. Carla also teaches entrepreneurship and strategy courses at the Carlson School of Management. She serves on two nonprofit boards: Social Venture Partners - Minnesota, which helps innovative nonprofits that focus on at-risk youth, and WomenVenture, which helps women entrepreneurs who have limited access to resources.


Fernando Bazan

J. Fernando Bazan was appointed Chief Technology Officer when he joined BioTechne on August 1, 2013. Following training at Stanford, Berkeley, and UCSF in biochemistry and biophysics, he led very active groups in biotherapeutics discovery as a senior scientist at DNAX Research Institute (now Merck Research Labs) and at Genentech (Roche). He also served as Chief Scientific Officer at NeuroScience, a neuroimmunology diagnostics startup. Dr. Bazan holds an adjunct faculty appointment in the Dept. of Pharmacology at the University of Minnesota School of Medicine.